BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24659184)

  • 1. Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma.
    Caffarel MM; Coleman N
    J Pathol; 2014 Mar; 232(4):386-90. PubMed ID: 24659184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
    Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
    J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness.
    Winder DM; Chattopadhyay A; Muralidhar B; Bauer J; English WR; Zhang X; Karagavriilidou K; Roberts I; Pett MR; Murphy G; Coleman N
    J Pathol; 2011 Nov; 225(3):448-62. PubMed ID: 21952923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma.
    Caffarel MM; Chattopadhyay A; Araujo AM; Bauer J; Scarpini CG; Coleman N
    J Pathol; 2013 Oct; 231(2):168-79. PubMed ID: 23765377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus and Host Events in Squamous Carcinogenesis.
    Coleman N
    Keio J Med; 2016; 65(4):78. PubMed ID: 28025425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival.
    Kucia-Tran JA; Tulkki V; Smith S; Scarpini CG; Hughes K; Araujo AM; Yan KY; Botthof J; Pérez-Gómez E; Quintanilla M; Cuschieri K; Caffarel MM; Coleman N
    Br J Cancer; 2016 Jul; 115(2):212-22. PubMed ID: 27351213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome.
    Ng G; Winder D; Muralidhar B; Gooding E; Roberts I; Pett M; Mukherjee G; Huang J; Coleman N
    J Pathol; 2007 Jul; 212(3):325-34. PubMed ID: 17516585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma.
    Kausar T; Sharma R; Hasan MR; Saraya A; Chattopadhyay TK; Gupta SD; Ralhan R
    Cell Oncol (Dordr); 2011 Jun; 34(3):177-87. PubMed ID: 21394648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M.
    Yu Z; Li Z; Wang C; Pan T; Chang X; Wang X; Zhou Q; Wu X; Li J; Zhang J; Liu B; Zhu Z; Su L
    Gastric Cancer; 2019 Sep; 22(5):955-966. PubMed ID: 30778797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
    Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
    Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma.
    Matsumoto Y; Ichikawa T; Kurozumi K; Otani Y; Fujimura A; Fujii K; Tomita Y; Hattori Y; Uneda A; Tsuboi N; Kaneda K; Makino K; Date I
    Acta Neuropathol Commun; 2020 Apr; 8(1):42. PubMed ID: 32248843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profile of pure squamous cell carcinoma of the bladder identifies major roles for OSMR and YAP signalling.
    Hurst CD; Cheng G; Platt FM; Alder O; Black EV; Burns JE; Brown J; Jain S; Roulson JA; Knowles MA
    J Pathol Clin Res; 2022 May; 8(3):279-293. PubMed ID: 35289095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels.
    Muralidhar B; Goldstein LD; Ng G; Winder DM; Palmer RD; Gooding EL; Barbosa-Morais NL; Mukherjee G; Thorne NP; Roberts I; Pett MR; Coleman N
    J Pathol; 2007 Aug; 212(4):368-77. PubMed ID: 17471471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WNT1, a target of miR-34a, promotes cervical squamous cell carcinoma proliferation and invasion by induction of an E-P cadherin switch via the WNT/β-catenin pathway.
    Li B; Guo X; Li N; Chen Q; Shen J; Huang X; Huang G; Wang F
    Cell Oncol (Dordr); 2020 Jun; 43(3):489-503. PubMed ID: 32301035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
    Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
    J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional evidence that Drosha overexpression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles.
    Muralidhar B; Winder D; Murray M; Palmer R; Barbosa-Morais N; Saini H; Roberts I; Pett M; Coleman N
    J Pathol; 2011 Aug; 224(4):496-507. PubMed ID: 21590768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BIRC2 Sensitizes α7-HPV-Related Cervical Squamous Cell Carcinoma to Chemotherapy.
    Lin CY; Wang CC; Wu RC; Yang LY; Chang CB; Pan YB; Chao A; Lai CH
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.
    West NR; Murphy LC; Watson PH
    Endocr Relat Cancer; 2012 Apr; 19(2):181-95. PubMed ID: 22267707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis.
    Wang F; Liu X; Yang P; Guo L; Liu C; Li H; Long S; Shen Y; Wan H
    Cell Death Dis; 2014 Mar; 5(3):e1133. PubMed ID: 24651436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Oncostatin M Signaling in Adipocytes Induces Insulin Resistance and Adipose Tissue Inflammation in Vivo.
    Elks CM; Zhao P; Grant RW; Hang H; Bailey JL; Burk DH; McNulty MA; Mynatt RL; Stephens JM
    J Biol Chem; 2016 Aug; 291(33):17066-76. PubMed ID: 27325693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.